Filing Details
HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event.
8k filedNASDAQ:HALO
HALOZYME THERAPEUTICS, INC. (HALO) Reports Material Event to SEC
Filing Details HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event. Market Context…
Market Context
HALOZYME THERAPEUTICS, INC.'s stock currently trades at $79.45 with a market capitalization of $7.3B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for HALOZYME THERAPEUTICS, INC.'s stock.
All SEC filings for HALOZYME THERAPEUTICS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View HALO Stock Page
Frequently Asked Questions
Where can I read HALO's SEC filings?
Browse all filings on our HALO SEC filings page.
What types of SEC filings does HALOZYME THERAPEUTICS, INC. file?
Public companies like HALOZYME THERAPEUTICS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.